Andrew Elnatan, M.Pharm

Brings over 20 years of biopharmaceutical regulatory experience in the development of early phase to marketed products, including therapeutic cancer vaccines, monoclonal antibodies for cancer, monoclonal antibodies for infectious diseases, vaccines for infectious diseases, and therapies for hematological rare-diseases.